(Q38111844)

29 August 2017

title

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. (English)

1 reference

29 August 2017

1 reference

3

Kris V Kowdley

1 reference

29 August 2017

Nihar Shah

1

1 reference

29 August 2017

Tracey Pierce

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

4 June 2013

1 reference

Expert Opinion on Investigational Drugs

29 August 2017

published in

1 reference

29 August 2017

volume

22

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

1107-1121

1 reference

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

The global burden of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Hepatitis C virus proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

The hepatitis C virus life cycle as a target for new antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

New direct-acting antivirals in the development for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Treatment of acute HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Product inhibition of the hepatitis C virus NS3 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Future treatment of patients with HCV cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Hepatitis C virus resistance to protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Exploratory study of oral combination antiviral therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

Acute Hepatitis C Infection: New Approaches to Surveillance, Treatment and Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.806482

10.1517/13543784.2013.806482

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference